Arnaud Gilles

Arnaud Gilles

Auto-generated profile, based on publicly available information

Arnaud Gilles

Adaptive Supramolecular Nanosystems Group, Institut Européen des Membranes, ENSCM-UMII-UMR-CNRS5635, Place Eugène Bataillon CC047, 34095 Montpellier Cedex 5 (France)

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2011 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
YDYann Le Duc
Yann Le Duc
MMMathieu Michau
Mathieu Michau
AGArnaud Gilles
Arnaud Gilles
VGValerie Gence
Valerie Gence
YLYves‐Marie Legrand
Yves‐Marie Legrand
Mihail BarboiuMihail Barboiu
Mihail Barboiu

8 April 2013 in Accounts of Chemical Research
Verified
Journal Article
Closed access
Mihail BarboiuMihail Barboiu
Mihail Barboiu
AGArnaud Gilles
Arnaud Gilles

30 December 2015 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
AGArnaud Gilles
Arnaud Gilles
MBMihail Barboiu
Mihail Barboiu

26 June 2014 in Nature Communications
Verified
Journal Article
Closed access
PDF file
MBMihail Barboiu
Mihail Barboiu
YDYann Le Duc
Yann Le Duc
AGArnaud Gilles
Arnaud Gilles
PCPierre-André Cazade
Pierre-André Cazade
MMMathieu Michau
Mathieu Michau
TFThomas Fyles
Thomas Fyles

1 August 2010 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
CMChristopher McGuigan
Christopher McGuigan
KMKarolina Madela
Karolina Madela
MAMohamed Aljarah
Mohamed Aljarah
AGArnaud Gilles
Arnaud Gilles
ABAndrea Brancale
Andrea Brancale
GHGeoffrey Henson
Geoffrey Henson

1 May 2011 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
JVJohn H. Vernachio
John H. Vernachio
BBBlair Bleiman
Blair Bleiman
KBK. Dawn Bryant
K. Dawn Bryant
SCStanley Chamberlain
Stanley Chamberlain
DHDamound Hunley
Damound Hunley
CMChristopher McGuigan
Christopher McGuigan
INX-08189 is an aryl-phosphoramidate of 6-O-methyl-2′-C-methyl guanosine. INX-08189 was highly potent in replicon assays, with a 50% effective concentration of 10 ± 6 nM against hepatitis C genotype 1b at 72 h. The inhibitory effect on viral replication was rapid, with a 50% effective concentration (EC50) of 35 ± 8 nM at 24 h. An intracellular 2′-C-methyl guanosine triphosphate (2′-C-MeGTP) concentration of 2.43 ± 0.42 pmol/106cells was sufficient to achieve 90% inhibition of viral replication.In vitroresistance studies confirmed that the S282T mutation in the NS5b gene conferred an approximately 10-fold reduction in sensitivity to INX-08189. However, the complete inhibition of S282T mutant replicons still could be achieved with an EC90of 344 ± 170 nM. Drug combination studies of INX-08189 and ribavirin indicated significant synergy in antiviral potency both in wild-type and S282T-expressing replicons. Genotype 1b replicons could be cleared after 14 days of culture when exposed to as little as 20 nM INX-08189. No evidence of mitochondrial toxicity was observed after 14 days of INX-08189 exposure in both HepG2 and CEM human cell lines.In vivostudies of rats and cynomolgus monkeys demonstrated that 2′-C-MeGTP concentrations in liver equivalent to the EC90could be attained after a single oral dose of INX-08189. Rat liver 2′-C-MeGTP concentrations were proportional to dose, sustained for greater than 24 h, and correlated with plasma concentrations of the nucleoside metabolite 2′-C-methyl guanosine. The characteristics displayed by INX-08189 support its continued development as a clinical candidate for the treatment of chronic HCV infection.